David Hutton

The Phase 1/2 Clinical Trial is for the treatment of retinitis pigmentosa and Leber congenital amaurosis.

According to researchers, using nanoparticles to encapsulate eye medication decreased graft rejection while requiring fewer and smaller doses.

According to researchers at the Max Planck Institute, the Kynurenine pathway is not only important for eye pigment formation, it also plays a role in maintaining retinal health.

Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.

The U.S. Attorney' Office Eastern District of Texas reported Kleiman Evangelista Eye Centers has agreed to pay $2,902,505 to resolve False Claims Act allegations that it offered and paid kickbacks to optometrists. In a statement, the practice said it settled the the civil action to avoid a protracted legal battle and remains committed to optimizing patient outcomes while continuing to work with its patients’ valued optometrists when patients choose to have their care co-managed.

Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

According to researchers, diabetes mellitus is caused by higher levels of blood glucose due to the lack of production of insulin by the body, resistance to insulin, or both.

According to the companies, NOV03 consistently met primary endpoints for the signs and symptoms of dry eye disease linked with Meibomian gland dysfunction. A PDUFA data is set for June 28.

Medicare reimbursements for complex cataract surgery are far lower than a simpler form of the surgery.

According to the company, it is the first approval in the world for allogeneic cell therapy to treat corneal endothelial disease.

BRIO-I is a double-masked, randomized, multi-center, safety and efficacy study that enrolled emmetropic phakic and pseudophakic presbyopic subjects.

Lessons learned from a pilot will inform future collaborative work between the ADA and Genentech to improve health equity in eye care for people living with diabetes.

Researchers are using a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing genetic mutations.

Medical student’s vision was threatened by keratoconus, and early diagnosis and treatment could prove to be key to preserving the patient’s vision.

PBM treatment showed a statistically significant slowing of disease progression in patients with early to intermediate dry AMD.

If approved, OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.

According to court records, Paul Wade Wyatt continued to perform ophthalmic procedures in Utah after his license had been suspended in October 2016.

Kamran M. Riaz, MD, a clinical associate professor and director of Medical Student Research at the Dean A. McGee Institute at the University of Oklahoma, recently discussed with Ophthalmology Times some of the latest trends in cornea treatment.

Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein.

The company plans to advance AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt disease, X-linked retinoschisis, and autosomal dominant optic atrophy.

The company has said it hopes to make the deals to be able to focus on its core areas.

According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.

The researchers from Indiana University School of Medicine found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.

Horizon Therapeutics presented data at the North American Neuro-Ophthalmology Society (NANOS) Annual Meeting, being held through March 16 in Orlando, Florida, summarizing real-world experience of people living with TED and DON who were treated with teprotumumab-trbw between January 2020 and September 2022.

While low-dose atropine eye drops are currently being used to slow myopia progression in several countries in Asia, researchers set out to determine if the medication could also the onset of myopia.

The researchers focused on photoreceptor cells (PRCs), which are light-detecting cells found in the retina.

According to the U.S. District Court, during the jury trial before U.S. District Judge Wilhelmina M. Wright, the United States proved that the defendants the Cameron-Ehlen Group, Inc., which does business as Precision Lens, and its owner Paul Ehlen paid kickbacks to ophthalmic surgeons to induce their use of Defendants’ products in cataract surgeries reimbursed by Medicare.